Table 2 Patient baseline characteristics

From: Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

 

Axitinib +

 

Paclitaxel/carboplatin, n =28

Gemcitabine/cisplatin, n =21

Male/female, n

21/7

9/12

Age, median (range), years

60 (37–75)

52 (40–79)

ECOG PS 0/1, n

16/12

9/12

Primary tumour type, n (%)

 NSCLC

17 (60.7)

0

 Melanoma

4 (14.3)

0

 Ovarian

3 (10.7)

1 (4.8)

 Pancreatic

0

4 (19.0)

 Breast

0

3 (14.3)

 Head and neck

1 (3.6)

1 (4.8)

 Cholangiocarcinoma

0

2 (9.5)

 CRC

0

2 (9.5)

 Other

3 (10.7)a

8 (38.1)b

Prior therapy, n (%)

 Surgery

14 (50.0)

20 (95.2)

 Radiotherapy

5 (17.9)

9 (42.9)

 Drug therapyc

8 (28.6)

15 (71.4)

  1. Abbreviations: CRC=colorectal cancer; ECOG PS=Eastern Cooperative Oncology Group performance status; NSCLC=non-small cell lung cancer.
  2. aRenal cell carcinoma, unknown primary tumour (n=2).
  3. bBladder, cervical, ectopic hormone secretion syndrome associated with neoplasia, gastrointestinal, prostate, sarcoma, small intestine, unknown primary tumour.
  4. cIncludes cytotoxic chemotherapy and targeted agents.
Back to article page